Longeveron Inc - נכסים נקיים למניה בודדת LGVN

Longeveron Inc. develops cellular anti-aging therapies, promising stable demand and high margins. The book value per share history demonstrates capital dynamics, where the 3.28 metric serves as the target level. Active R&D in the field of Alzheimer's disease is complemented by a production and logistics outsourcing strategy to optimize operational processes.

The book value per share, which stands at 3.28, determines the portion of net assets attributable to a single security and serves as an indicator of the asset-backed protection of investor capital. The dynamics of equity per share reflect the capitalization rate of Longeveron Inc. (LGVN), where growth in this metric confirms the company's financial stability during critical clinical trials of Alzheimer's disease therapies.